{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:46:40Z","timestamp":1789958800963,"version":"4.0.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":3567,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.exphem.2012.05.010","type":"journal-article","created":{"date-parts":[[2012,5,31]],"date-time":"2012-05-31T22:19:46Z","timestamp":1338502786000},"page":"705-714.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients"],"prefix":"10.1016","volume":"40","author":[{"given":"Sari E.","family":"Jalkanen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Lahesmaa-Korpinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Heckman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ville","family":"Rantanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sampsa","family":"Hautaniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2012.05.010_bib1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2012.05.010_bib2","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.010_bib3","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.exphem.2012.05.010_bib4","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2012.05.010_bib5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.beha.2009.10.001","article-title":"Response definitions and European Leukemianet Management recommendations","volume":"22","author":"Baccarani","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.exphem.2012.05.010_bib6","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2012.05.010_bib7","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2012.05.010_bib8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.010_bib9","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.exphem.2012.05.010_bib10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.010_bib11","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.leu.2404227","article-title":"Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis","volume":"20","author":"Zheng","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2012.05.010_bib12","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2012.05.010_bib13","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/sj.leu.2404197","article-title":"Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach","volume":"20","author":"Villuendas","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2012.05.010_bib14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/1078-0432.CCR-0784-3","article-title":"Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib","volume":"10","author":"McLean","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2012.05.010_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2005-05-2155","article-title":"Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML","volume":"107","author":"Yong","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.010_bib16","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1182\/blood-2006-12-065599","article-title":"The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia","volume":"110","author":"Mohty","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.010_bib17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.leukres.2011.06.011","article-title":"Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"36","author":"Guillem","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.exphem.2012.05.010_bib18","first-page":"459","article-title":"In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures","volume":"90","author":"Crossman","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.exphem.2012.05.010_bib19","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"28","author":"White","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2012.05.010_bib20","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.010_bib21","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/leu.2011.180","article-title":"KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib","volume":"26","author":"Marin","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2012.05.010_bib22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/gm186","article-title":"Large-scale data integration framework provides a comprehensive view on glioblastoma multiforme","volume":"2","author":"Ovaska","year":"2010","journal-title":"Genome Med"},{"key":"10.1016\/j.exphem.2012.05.010_bib23","doi-asserted-by":"crossref","first-page":"10538","DOI":"10.1073\/pnas.190104497","article-title":"Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR\/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of\u00a0regulating cdk2 activity","volume":"97","author":"Jiang","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2012.05.010_bib24","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/leu.2010.24","article-title":"Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors","volume":"24","author":"Chu","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2012.05.010_bib25","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","article-title":"P210 and P190(BCR\/ABL) induce the\u00a0tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members","volume":"271","author":"Ilaria","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2012.05.010_bib26","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.4049\/jimmunol.159.10.4720","article-title":"Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients","volume":"159","author":"Chai","year":"1997","journal-title":"J Immunol"},{"key":"10.1016\/j.exphem.2012.05.010_bib27","first-page":"247","article-title":"Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia","volume":"13","author":"Shuai","year":"1996","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2012.05.010_bib28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/blood.V45.3.321.321","article-title":"Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome","volume":"45","author":"Lozzio","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.010_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2010.09.005","article-title":"Poor cytokine-induced phosphorylation in chronic myeloid leukemia patients at diagnosis is effectively reversed by tyrosine kinase inhibitor therapy","volume":"39","author":"Jalkanen","year":"2011","journal-title":"Exp Hematol"},{"key":"10.1016\/j.exphem.2012.05.010_bib30","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","article-title":"High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia","volume":"117","author":"Warsch","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.010_bib31","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1046\/j.0902-4441.2003.00201.x","article-title":"Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients","volume":"72","author":"Gutierrez-Castellanos","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.exphem.2012.05.010_bib32","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/onc.2009.374","article-title":"Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR\/p70S6-kinase pathway","volume":"29","author":"Markova","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2012.05.010_bib33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/sj.leu.2402778","article-title":"The interaction of the Bcr-Abl tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains","volume":"17","author":"Stanglmaier","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2012.05.010_bib34","doi-asserted-by":"crossref","first-page":"18581","DOI":"10.1074\/jbc.C000126200","article-title":"Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck","volume":"275","author":"Lionberger","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2012.05.010_bib35","doi-asserted-by":"crossref","first-page":"21446","DOI":"10.1074\/jbc.M109.090043","article-title":"Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner","volume":"285","author":"Pene-Dumitrescu","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2012.05.010_bib36","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2012.05.010_bib37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2012.05.010_bib38","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2012.05.010_bib39","doi-asserted-by":"crossref","first-page":"8605","DOI":"10.1038\/sj.onc.1206088","article-title":"Mechanisms underlying abnormal trafficking and expansion of malignant progenitors in CML: BCR\/ABL-induced defects in integrin function in CML","volume":"21","author":"Salesse","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2012.05.010_bib40","doi-asserted-by":"crossref","first-page":"29145","DOI":"10.1074\/jbc.270.49.29145","article-title":"CRKL links p210BCR\/ABL with paxillin in chronic myelogenous leukemia cells","volume":"270","author":"Salgia","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.exphem.2012.05.010_bib41","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/sj.leu.2403310","article-title":"p210BCR\/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells","volume":"18","author":"Salesse","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2012.05.010_bib42","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2012.05.010_bib43","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.canlet.2011.08.002","article-title":"Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65\u2014a novel Wnt\/beta-catenin signaling inhibitor","volume":"312","author":"Nagao","year":"2011","journal-title":"Cancer Lett"},{"key":"10.1016\/j.exphem.2012.05.010_bib44","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1007\/s00018-009-0086-3","article-title":"Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology","volume":"66","author":"Kostenko","year":"2009","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.exphem.2012.05.010_bib45","article-title":"Immunohistochemical detection of HSP27 and hnRNP K as prognostic and predictive biomarkers for colorectal cancer","author":"Wang","year":"2011","journal-title":"Med Oncol"},{"key":"10.1016\/j.exphem.2012.05.010_bib46","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.juro.2006.09.073","article-title":"Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy","volume":"177","author":"Kurahashi","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.exphem.2012.05.010_bib47","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/sj.bjc.6605227","article-title":"Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement","volume":"101","author":"Foster","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.exphem.2012.05.010_bib48","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00432-002-0357-y","article-title":"Expression of the 27-kDa heat shock protein (HSP27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance","volume":"128","author":"Kapranos","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.exphem.2012.05.010_bib49","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1002\/pmic.200401309","article-title":"Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis","volume":"5","author":"Feng","year":"2005","journal-title":"Proteomics"},{"key":"10.1016\/j.exphem.2012.05.010_bib50","first-page":"1649","article-title":"Heat shock protein 27 is associated with decreased survival in node-negative breast cancer patients","volume":"25","author":"Thanner","year":"2005","journal-title":"Anticancer Res."},{"key":"10.1016\/j.exphem.2012.05.010_bib51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13277-010-0088-7","article-title":"Heat-shock protein expression in leukemia","volume":"32","author":"Sedlackova","year":"2011","journal-title":"Tumour Biol"},{"key":"10.1016\/j.exphem.2012.05.010_bib52","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1189\/jlb.0709502","article-title":"Differential heat shock protein localization in chronic lymphocytic leukemia","volume":"87","author":"Dempsey","year":"2010","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.exphem.2012.05.010_bib53","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.leukres.2005.02.010","article-title":"Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia","volume":"29","author":"Thomas","year":"2005","journal-title":"Leuk Res"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X12001853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X12001853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:30:16Z","timestamp":1759566616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X12001853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":53,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0301472X12001853"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2012.05.010","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2012.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}